Dana–Farber Cancer Institute

Time to Sustained Improvement in Bowel Movement Frequency With Telotristat Ethyl: Analysis of the Phase 3 TELESTAR Study (2018) Dillon JS, Kulke MH, Pavel ME, Horsch D, Anthony LB, Warner RRP, Bergsland E, et al. Conference contribution Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial (2018) Pavel M, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, et al. Conference contribution Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome (2018) Dillon J, Kulke M, Warner R, Bergsland E, Welin S, O'Dorisio T, Mckee C, et al. Conference contribution Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation (2017) Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, et al. Journal article Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent (2017) Richardson P, Roy A, Acharyya S, Panneerselvam A, Mendelson E, Guenther A, Lonial S, Einsele H Journal article Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma (2017) Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, et al. Journal article Efficacy and safety of nilotinib in patients with kit-mutated metastatic or inoperable melanoma: Final results from the global, single-arm, phase ii team trial (2017) Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, et al. Journal article Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group (2017) Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, et al. Journal article, Review article Deacetylase inhibitors: an advance in myeloma therapy? (2017) Laubach JP, San-Miguel JF, Hungria V, Hou J, Moreau P, Lonial S, Lee JH, et al. Journal article, Review article Second primary malignancies in multiple myeloma: An overview and IMWG consensus (2017) Musto P, Anderson KC, Attal MM, Richardson PG, Badros A, Hou J, Comenzo R, et al. Journal article, Review article